Methotrexate: A Membrane-Aware Assay Framework
2026-08-18
Methotrexate is more than a folate antagonist: its ionization, cellular uptake, and polyglutamate retention shape experimental outcomes. This guide connects biomimetic membrane chromatography with apoptosis, proliferation, and immunosuppression assay design.
Masitinib (AB1010): KIT/PDGFR Workflow Guide
2026-08-18
Masitinib (AB1010) provides a DMSO-compatible approach for studying KIT, PDGFRα, and PDGFRβ signaling in cancer, mast cell, and inflammatory models. It is appropriate for defined kinase-inhibition workflows, but not for aqueous or ethanol-based protocols or experiments requiring broad-spectrum kinase suppression.
4-MUG for Translational Lysosomal Assays
2026-08-17
4-Methylumbelliferyl-β-D-Glucopyranoside (4-MUG) converts β-glucosidase activity into a sensitive fluorescent signal. This guide focuses on how to design, interpret, and translate 4-MUG assays for Gaucher disease and GBA1-mRNA research.
Vemurafenib (PLX4032) in Melanoma Research
2026-08-16
Vemurafenib (PLX4032) provides a controlled pharmacological perturbation of mutant BRAF signaling for melanoma cell proliferation inhibition, resistance profiling, and xenograft studies. This workflow connects dose-response experiments with early phospho-signaling and multi-omics readouts to distinguish target engagement from adaptive resistance.
Hybrid Core-Shell Particles for Systemic mRNA Delivery
2026-08-15
The reference study developed hyaluronic-acid-coated liposome–mRNA complexes as hybrid core-shell nanoparticles for systemic delivery. By comparing uncoated and coated particles across physicochemical, cellular, and mouse biodistribution studies, it showed that surface charge can be tuned without major loss of mRNA binding or transfection activity, while particle accumulation and protein expression occurred in different tissues.
Angiotensin 1/2 (2-7): Assay Design Guide
2026-08-15
Explore how Angiotensin 1/2 (2-7) peptide can support mechanistic renin-angiotensin and receptor-binding studies. This guide connects peptide chemistry, assay design, and recent SARS-CoV-2 spike-binding evidence while defining important translational limits.
Soluble PD-L1 in Glioma: Wnt/β-Catenin Mechanism
2026-08-14
The reference study identifies glioma cells as a source of soluble PD-L1 and links its production to Wnt/β-catenin signaling, extending soluble PD-L1 research beyond prognostic association. Its findings connect plasma biomarker levels with tumor burden and CD8+ T-cell suppression, while supporting combined Wnt and PD-L1 blockade as a preclinical strategy.
Dihydroartemisinin: From Reagent to Assay Logic
2026-08-14
Dihydroartemisinin is more than a familiar Artemisia-derived antimalarial: its value depends on how chemical identity, exposure, pathway readouts, and comparator biology are aligned. This guide provides an assay-centered framework for malaria, mTOR, psoriasis, and inflammation research while separating evidence from practical recommendations.
4-Hydroxytamoxifen: Practical Lab Guide
2026-08-13
4-Hydroxytamoxifen (SKU B6167) provides a characterized estrogen receptor modulator for DMSO-compatible cell and animal research workflows, including breast cancer research, prostate cancer research, and cardiac myocyte studies. It should not be selected for protocols that require aqueous or ethanol-based dosing unless a separate formulation and compatibility procedure has been validated.
C34 TLR4 Inhibitor: Reliable Assay Workflows
2026-08-13
Learn how C34 (CAS 40592-88-9) TLR4 Inhibitor, SKU B4925, can improve interpretation of viability, proliferation, and inflammatory signaling assays. This scenario-based guide covers selectivity, dosing, controls, storage, cross-model interpretation, and practical product selection.
Calpain Inhibitor I, ALLN: Practical Protocol
2026-08-12
Calpain Inhibitor I, ALLN (SKU A2602) provides a research tool for testing calpain- and cathepsin-associated proteolysis in apoptosis, inflammation, and ischemia-reperfusion workflows. It is intended for controlled scientific experiments only; product dossier values do not replace assay-specific optimization or establish clinical, diagnostic, or therapeutic use.
Arsenic, MMP-2/9, and BBB Cognitive Injury
2026-08-12
A 2024 mouse study connects chronic sodium arsenite exposure with cognitive impairment through MMP-2/MMP-9-associated blood–brain barrier disruption and hippocampal neuronal apoptosis. Doxycycline hyclate intervention preserved barrier-related proteins and improved behavioral outcomes, providing a pharmacological framework for studying MMP-dependent neurotoxicity while leaving questions about specificity and translation unresolved.
ω-Agatoxin IVA TFA: From Blockade to Assay Design
2026-08-11
ω-Agatoxin IVA TFA is a selective Cav2.1 channel probe for connecting calcium influx with neurotransmitter release. This guide focuses on assay design, concentration logic, and how to interpret neuronal, epilepsy, and neuroprotection data without overextending the evidence.
HyperFluor™ 488 Rabbit Anti-Goat IgG Workflow
2026-08-10
Build sensitive fluorescence workflows around a broadly reactive, affinity-purified secondary for goat primary antibodies across tissue, cell, blot, and cytometry assays. This guide translates a high-altitude hypoxia study into practical staining, imaging, control, and troubleshooting decisions.
Estradiol Benzoate: ERα Binding to Assay Design
2026-08-09
Estradiol Benzoate is an estrogen receptor alpha agonist suited to mechanistic receptor studies. This article presents an evidence-centered framework for translating ERα binding data, solvent considerations, and structure-based screening logic into more reproducible assay decisions.
458 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page